| Identification | Back Directory | [Name]
1H-Indazole-6-sulfonamide, 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-N-(1-methylcyclopropyl)- | [CAS]
2988890-20-4 | [Synonyms]
| [Molecular Formula]
C20H25F2N7O2S2 | [MOL File]
2988890-20-4.mol | [Molecular Weight]
497.59 |
| Chemical Properties | Back Directory | [Boiling point ]
680.7±65.0 °C(Predicted) | [density ]
1.65±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
11.45±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1]. | [References]
[1] Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1. |
|
|